期刊文献+

COX-2及P53在乳腺癌中的表达及临床意义 被引量:2

原文传递
导出
摘要 目的:检测乳腺癌中COX-2及P53的表达,探讨其表达的临床意义。方法:应用免疫组织化学技术检测52例乳腺癌组织中的COX-2及P53的表达。结果:乳腺癌组织中COX-2及P53均呈强阳性表达,且COX-2的阳性表达与乳腺癌分化程度、临床分期及淋巴结转移有关,差异有统计学意义(P<0.05),而与癌肿大小无关,差异无统计学意义(P>0.05);P53的阳性表达与乳腺癌临床分期及淋巴结转移有关,差异有统计学意义(P<0.05),而与癌组织分化程度及癌肿大小无关,差异无统计学意义(P>0.05)。结论:COX-2及P53在乳腺癌的发生、发展中起重要作用。
出处 《中国妇幼保健》 CAS 北大核心 2014年第16期2523-2524,共2页 Maternal and Child Health Care of China
  • 相关文献

参考文献8

二级参考文献74

  • 1李宝江,朱志华,王军业,侯景辉,赵进明,张蓬原,姚广裕,王曦,龙浩,杨名添,戎铁.Ki67、P53、VEGF和C-erbB-2在乳腺癌组织中表达的相关性研究及其临床意义[J].癌症,2004,23(10):1176-1179. 被引量:126
  • 2左连富,齐风英,刘江惠,郭建文.乳腺癌P53基因蛋白的表达与临床预后的关系[J].癌症,1995,14(4):252-255. 被引量:13
  • 3高海燕,杜金荣,陈英准,付红.VEGF-C、p53和C-erbB-2在乳腺癌中的表达及意义[J].哈尔滨医科大学学报,2007,41(1):49-51. 被引量:8
  • 4刘新杰,罗民,周冬仙,麦沛成,周文斌.Ki-67在乳腺癌中的表达及相关性研究[J].中国医师进修杂志(外科版),2007,30(6):5-7. 被引量:2
  • 5宋印利 孙淑娟 张清媛.COX-2与VEGF在乳腺癌中的表达及临床意义.当代医学,2008,63(3):98-98.
  • 6Morris CD,Armstrong GR,Bigley G,et al.Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence[J].Am J Gastroenterol,2001,96 (4):990-996.
  • 7Liu CH,Chang SH,Narko K,et al.Overexpression of cyclooxygenase-2 is sufficien to induce tumorigenesis in transgenicmice[J].Biol Chem,2001,276 (21):18563-18569.
  • 8Ristimki A,Sivula A,Lundin J,et al.Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer[J].Cancer Res,2002,62 (3):632-635.
  • 9Denkert C,Winzer KJ,Muller BM,et al.Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma[J].Cancer,2003,97(12):2978-2987.
  • 10Wü lfing P,Diallo R.Analysis of cyclooxygenase-2 expression in human breast cancer:high throughput tissue microarray analysis[J].J Cancer Res Clin Oncol,2003,129 (7):375-382.

共引文献20

同被引文献29

  • 1DURAI PC, THAPPA DM, KUMARI R, et al. Aging in elderly: chronological versus photoaging[J]. Indian J Dermatol, 2012, 57(5): 343-352.
  • 2BIANCHINI F, MASSI D, MARCONI C, et al. Expression of eyclooxygenase-2 in macrophages associated with cutaneous melanoma at diverent stages of progression[J]. Prostaglandins Oth- er Lipid Mediat, 2007, 83: 320-328.
  • 3CHWIROT BW, KUZBICKI L. Cycleoxygenase-2 (COX-2): first marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours[J]. Melanoma Res, 2007, 17: 139-145.
  • 4RAGHAVENDRA G, SUBBARAO VM, DHIMANT D, et al. Si- multaneous targeting of COX-2 GSH to inhibit melanoma[J]. Mol and AKT using selenocoxib-1- Cancer Ther, 2013, 12(1): 3-15.
  • 5MARYAM S, SHAHRYAR S, SEPIDEH S, et al. Cyclooxyge- nase-2 expression in oral squamous cell carcinoma[J]. Journal of Cancer Research and Therapeutics, 2014, 10(4): 1024-1029.
  • 6JOHANSSON CC, EGYHAZI S, MASUCCI G, et al. Prognostic significance of tumor iNOS and COX-2 in stage malignant cutaneous melanoma[J]. Cancer Immunol Immunother, 2009, 58(7): 1085-1094.
  • 7BECKER MR, SIEGELIN MD, ROMPEL R, et al. COX-2 ex- pression in malignant melanoma: a novel prognostic marker[J]. Melanoma Res, 2009, 19(1): 8-16.
  • 8KUZBICKI L, LANGE D, STRACZYlqSKA-NIEMIEC A, et al. The value of cycleoxygenase-2 expression in differentiating be- tween early melanomas and histopathologically difficult types of benign human skin lesions[J]. Melanoma Research, 2012, 22(t): 70-76.
  • 9YI C, ZHANG Y, YU Z, et al. Melatonin enhances the an- ti-tumor effect of fisetin by inhibiting COX-2/iNOS and NF-K B/p300 signaling pathways[j]. PloS One, 2014, 9(7): 1-11.
  • 10RAO DS, GUI D, KOSKI ME, et al. An inverse relation be- tween COX-2 and E-cadherin expression correlates with ag- gressive histologic features in prostate cancer [J]. Appl Immuno- histochem Mol Morphol, 2006, 14: 375-383.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部